Farallon Capital Management LLC Acquires 278,700 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Farallon Capital Management LLC lifted its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,570,700 shares of the company's stock after acquiring an additional 278,700 shares during the period. Farallon Capital Management LLC owned 4.71% of Voyager Therapeutics worth $14,576,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Voyager Therapeutics by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company's stock valued at $18,232,000 after purchasing an additional 29,014 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Geode Capital Management LLC lifted its stake in Voyager Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock valued at $6,149,000 after purchasing an additional 4,729 shares during the last quarter. Northern Trust Corp lifted its stake in Voyager Therapeutics by 3.0% during the fourth quarter. Northern Trust Corp now owns 418,745 shares of the company's stock valued at $2,374,000 after purchasing an additional 12,374 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Voyager Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 261,251 shares of the company's stock valued at $1,481,000 after purchasing an additional 31,882 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on VYGR. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group dropped their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th. Finally, Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of "Buy" and an average price target of $13.97.

Insider Activity

In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares of the company's stock, valued at $1,478,093.33. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.39% of the stock is owned by company insiders.

Voyager Therapeutics Trading Down 5.5%

Shares of Voyager Therapeutics stock traded down $0.19 during trading on Friday, reaching $3.24. The stock had a trading volume of 756,113 shares, compared to its average volume of 445,858. The company has a market capitalization of $179.21 million, a price-to-earnings ratio of 4.56 and a beta of 0.95. The stock has a fifty day moving average price of $3.52 and a two-hundred day moving average price of $4.91. Voyager Therapeutics, Inc. has a 52 week low of $2.75 and a 52 week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. On average, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.